SCHEMBL6716867

SCHEMBL6716867

Cc1ccccc1NC(=O)C(N)C1=CC(=S)CC=C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.42
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
HPGD P15428 3/20 0.40
ALDH1A1 P00352 1/20 0.40
PGR P06401 1/20 0.40
SCN1A P35498 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
TSHR P16473 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
DDX3X O00571 2/20 0.38
EPHX1 P07099 1/20 0.38
ITGB3 P05106 1/20 0.37
ITGB1 P05556 1/20 0.37
ITGAV P06756 1/20 0.37
ITGA5 P08648 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6824933 0.84 POLB (0.41) POLBRAB9ANPC1HPGDALDH1A1
SCHEMBL6723693 0.76 KMT2A (0.43) POLBRAB9AHPGDALDH1A1PGR
SCHEMBL6718687 0.71 RAB9A (0.55) POLBRAB9ANPC1HPGDALDH1A1
SCHEMBL28609335 0.71 RAB9A (0.55) POLBRAB9ANPC1HPGDALDH1A1
SCHEMBL6718773 0.71 RAB9A (0.55) POLBRAB9ANPC1HPGDALDH1A1
SCHEMBL6723897 0.69 MAPT (0.49) POLBRAB9ANPC1HPGDALDH1A1
SCHEMBL8346804 0.69 NPC1 (0.60) POLBRAB9ANPC1HPGDALDH1A1
SCHEMBL8344357 0.69 NPC1 (0.60) POLBRAB9ANPC1HPGDALDH1A1
Formic Acid SCHEMBL6717292 0.67 CYP1A2 (0.53) POLBRAB9ANPC1HPGDALDH1A1
Formic Acid SCHEMBL6715482 0.67 CYP1A2 (0.53) POLBRAB9ANPC1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 POLB 4182/4885RAB9A 2094/4885NPC1 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.